Window of Opportunity Study of Pre-Operative Atezolizumab (ANTI PD-L1 ANTIBODY) for Patients with Resectable HPV Related Oropharyngeal Squamous Cell Carcinoma (OPSCC)

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

Window of Opportunity Study of Pre-Operative Atezolizumab (ANTI PD-L1 ANTIBODY) for Patients with Resectable HPV Related Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Oropharyngeal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

30 Mar 2025 Planned End Date changed from 4 Aug 2026 to 16 Dec 2026.
30 Mar 2025 Planned primary completion date changed from 4 Aug 2025 to 16 Dec 2025.
18 Mar 2024 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com